SBR
Financiado
SMART BONE REGENERATION
The management and reconstruction of bone defects is a significant global healthcare challenge. While autografts offer ideal compatibility, they are often not suitable for large bone defects, and allografts suffer from potential i...
The management and reconstruction of bone defects is a significant global healthcare challenge. While autografts offer ideal compatibility, they are often not suitable for large bone defects, and allografts suffer from potential immunorejection.The limited efficacy of conventional treatment strategies for large bone defects and the increasing aged population, has inspired the consortium to propose a SMART RESORBABLE BONE (SRB) IMPLANT embedding stem cells and bioactive agents with the aim of a controllable and fast restoration. The proposed solution includes 3D printed medical grade polymers enriched with electrospun fibers (for increased mechanical properties) that can be customized for patient physiology, pathology, and gender. The scaffold design will ensure easy and minimal Injury placement, and will embed different sensors for monitoring e.g. pressure, pH value and temperature based on biocompatible conductive inks. The smart implant will thus be able to provide vital information of implant performance in terms of bone growth and infection/inflammation. The proposed method is unique because it includes a customized smart implant (3D printed parts with adjustable sensors and communication electronic system), together with tissue engineering methods i.e. in-vitro programming of stem cells for embedding into the smart implant. The proposed solution introduces an innovative regenerative chain, from early testing and characterization (identification/adjustement of the proper specifications) and embedding regenerative stem cells and particulate bioactive agents into the smart implant in preclinical research (in-vitro). The in vivo proof of concept of SBR solution will be tested in (large animal model) preclinical studies within the scope of the project. Finally the regulatory and commercialization strategy on how to further explore the proposed concept and deliver it for clinical testing will be elaborated.
ver más
Duración del proyecto: 61 meses
Fecha Inicio: 2019-11-24
Fecha Fin: 2024-12-31
Fecha Fin: 2024-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-11-24
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
SC1-BHC-07-2019:
Regenerative medicine: from new insights to new applications
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
PANEPISTIMIO PATRON
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
643.13K€ |
Participante
619.72K€ |
Participante